|
|
A2.1 Cells : HLA-A2.1 Control Cell Lines or Slides
STAR Multimer Staining Control Cell Lines
HLA-A2.1 control cells express HLA-A2.1 on their surface. These cells have been loaded with HLA-A2.1 restricted peptides to serve as positive controls for antigen-specific staining with STAR multimers. Cells are supplied in frozen suspension for flow cytometry application and as frozen cytospin-prepared slides for immunohistochemistry.
View Product Sheet
Peptide Loaded | No peptide p53-264 (aa264-272): LLGRNSFEV p53-149 (aa149-157) : STPPPGTRV CMV-pp65 (aa495-503): NLVPMVATV gp100:209-217(210M) analog: IMDQVPFSV MART-1:26-35(27L) analog: ELAGIGILTV
|
Format | Control Slide (each slide contains two panels of cytospin-prepared cells loaded or not loaded with peptide) |
Size | Cell Suspension - 1x106 cells per 1 mL vial, or custom sizes upon request Control Slide - 1 slide per pack (two panels)
|
Application | Control cell lines/td> |
Storage Condition | Store at -70°C
|
For help with your order please contact:
Altor Store Customer Support
Phone: (954) 443-8600 or email: sales@altorbioscience.com
|
| CA2-XC1-1000 |
HLA-A2.1 restricted, No Peptide, Cell Suspension
|
$180.00 |
|
|
| CA2-AC1-1000 |
HLA-A2.1 restricted, Peptide: p53-264, Cell Suspension
|
$220.00 |
|
|
| CA2-BC1-1000 |
HLA-A2.1 restricted, Peptide: p53-149, Cell Suspension
|
$220.00 |
|
|
| CA2-CC1-1000 |
HLA-A2.1 restricted, Peptide: CMV-pp65, Cell Suspension
|
$220.00 |
|
|
| CA2-DC1-1001 |
HLA-A2.1 restricted, Peptide: gp100:209-217(210M), Cell Suspension
|
$220.00 |
|
|
| CA2-EC1-1002 |
HLA-A2.1 restricted, Peptide: MART-1:26-35(27L), Cell Suspension
|
$220.00 |
|
|
| CA2-AC2-0001 |
HLA-A2.1 restricted, Peptide: p53-264 (with & W/o), Cryo-Slide
|
$220.00 |
|
|
| CA2-BC2-0001 |
HLA-A2.1 restricted, Peptide: p53-149 (with & w/o), Cryo-Slide
|
$220.00 |
|
|
| CA2-CC2-0001 |
HLA-A2.1 restricted, Peptide: CMV-pp65 (with & w/o), Cryo-Slide
|
$220.00 |
|
Product Central
Product Inserts
MSDS
Product Literature
Privacy Policy
Terms and Conditions
Support
© Altor BioScience Corporation, 2011
|
|